文献速递瓣膜外科

退行性二尖瓣反流真实世界手术结局与修复率:MITRACURE 登记研究

Contemporary surgical outcomes and repair rates in degenerative mitral regurgitation: Real-world insights from the international MITRACURE registry.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-05-04

基于加拿大和法国40中心2019年连续成人二尖瓣反流手术患者的MITRACURE多中心登记,筛选退行性二尖瓣反流2135例。修复率80%,院内死亡率2.3%(修复1.4%对置换6.2%,P<.0001),主要并发症20%。高龄、合并症和复杂解剖降低修复率,高容量中心修复率更高(68%、77%、84%,P<.0001)。

要点

  • 退行性二尖瓣反流手术修复率80%,术中修复失败率6%,院内死亡率2.3%。
  • 修复与置换院内死亡率分别为1.4%和6.2%(P<.0001),主要并发症发生率20%。
  • 高容量中心修复率84%,高于中等77%和低容量68%(P<.0001)。

核心结论

  • 在该大型真实世界队列中,许多退行性二尖瓣反流患者转诊手术较晚,早期干预罕见。
  • 总体院内死亡率低但亚组间存在差异,二尖瓣修复率随年龄和瓣膜解剖复杂性增加而下降。
  • 高容量中心结局更好,支持早期转诊、结构化路径和手术集中化以优化诊疗。

研究设计与样本

  • MITRACURE为加拿大和法国40中心的多中心登记,纳入2019年连续接受二尖瓣反流手术的成人患者。
  • 本研究选取其中退行性二尖瓣反流患者2135例(70%男性,65±12岁)。

主要发现

  • 37%患者为NYHA III/IV级,仅17%被认为无症状,仅4%接受早期干预。
  • 二尖瓣修复率80%,术中修复失败率6%;院内死亡率2.3%,修复1.4%对置换6.2%(P<.0001)。
  • 主要并发症发生于20%患者,置换和联合手术者更高。
  • 死亡独立预测因素包括NYHA III/IV、手术类型和欧洲心脏手术风险评估系统II(EuroSCORE II)。
  • 修复率随年龄、合并症和复杂解剖下降,随中心容量增加而升高(低、中、高容量中心分别为68%、77%、84%,P<.0001)。

关键数值与推荐

  • 二尖瓣修复率80%,术中修复失败率6%。
  • 院内死亡率2.3%:修复1.4%对置换6.2%(P<.0001)。
  • 主要并发症发生率20%。
  • 低、中、高容量中心修复率分别为68%、77%、84%(P<.0001)。

临床怎么用

  • 对退行性二尖瓣反流患者应考虑早期转诊,避免因延迟导致NYHA III/IV级比例升高。
  • 高容量中心修复率更高,支持将手术集中化并建立结构化诊疗路径。
  • 年龄大、合并症多和解剖复杂者修复率较低,术前应充分评估修复可行性。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Degenerative mitral valve disease is the leading mitral regurgitation etiology in Western countries, representing a significant health burden. With the rise of transcatheter therapies, real-world data on surgical management, repair rates, outcomes, and center-level practices are increasingly needed. METHODS: From MITRACURE, a multicenter registry of 40 centers across Canada and France of consecutive adult patients who underwent surgery for mitral regurgitation in 2019, we selected the subset of patients with degenerative mitral regurgitation. RESULTS: Mitral valve surgery was performed in 2135 patients with degenerative mitral regurgitation (70% male, 65 ± 12 years); 37% were in New York Heart Association III/IV, only 17% were considered asymptomatic, and early intervention was performed in only 4%. Mitral valve repair rate was 80%, with a 6% intraoperative repair failure rate. In-hospital mortality was 2.3%: 1.4% for repair versus 6.2% for replacement (P < .0001). Major complications occurred in 20% of patients and was higher for replacement and combined procedures. Independent predictors of mortality included New York Heart Association III/IV, type of surgery, and European System for Cardiac Operative Risk Evaluation II. Repair rates declined with age, comorbidities, and complex anatomy, and increased with center volume (68%, 77%, and 84% in low-, intermediate-, and high-volume centers, respectively; P < .0001). Sex was not associated with repair rates after adjustment. CONCLUSIONS: In this large real-world cohort from 2 publicly funded healthcare systems, many patients with degenerative mitral regurgitation were referred late for surgery, and early intervention was rare. Although in-hospital mortality was low overall, outcomes varied across subgroups. Mitral valve repair declined with age and mitral valve anatomic complexity. High-volume centers had better outcomes, supporting earlier referral, structured pathways, and surgical centralization to optimize care.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Bouchard D, Dreyfus J, Tourneau TL, et al. Contemporary surgical outcomes and repair rates in degenerative mitral regurgitation: Real-world insights from the international MITRACURE registry. J Thorac Cardiovasc Surg. 2026. PMID: 42092496. doi:10.1016/j.jtcvs.2026.03.605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。